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Abstract: Respiratory tract infections are a global health problem. The main causative agents of these
infections are influenza A virus (IAV), Staphylococcus aureus (S. aureus), and Streptococcus pneumoniae
(S. pneumoniae). Major research focuses on genetics and immune responses in these infections.
Eicosanoids and other oxylipins are host-derived lipid mediators that play an important role in the
activation and resolution of inflammation. In this study, we assess, for the first time, the different
intracellular profiles of these bioactive lipid mediators during S. aureus LUG2012, S. pneumoniae TIGR4,
IAV, and corresponding viral and bacterial co-infections of 16HBE cells. We observed a multitude of
altered lipid mediators. Changes in the amount of 5-hydroxyeicosatetraenoic acid (5-HETE) were
prominent for all bacterial infections. The infection with S. pneumoniae showed the strongest impact
on bioactive lipid production and led to alterations in the amount of PPARγ ligands and precursors
of pro-resolving lipid mediators.
Keywords: eicosanoids; lipid mediators; oxylipins; respiratory tract infection; co-infection; S. aureus;
S. pneumoniae; influenza A virus
1. Introduction
Infections of the respiratory tract are the fourth most common reason for the cause of mortality
worldwide [1]. Major pathogens causing such infections are influenza A virus (IAV) [2], Staphyloccocus
aureus (S. aureus), including methicillin-resistant strains of the USA300 lineage, and Streptococcus
pneumoniae (S. pneumoniae) [3]. There is evidence that bacterial and viral co-infections even accelerate
the mortality rate as compared to infections by single agents [4]. The immune system plays a major
role in the recognition and elimination of the pathogens, which can be influenced by bioactive lipids.
Such bioactive lipid mediators are eicosanoids. They play a role in, e.g., induction and resolution
of inflammation [5–7]. These oxidized unsaturated fatty acids are synthesized from arachidonic
acid (AA), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and linoleic acid (LA) [8].
The main enzymes responsible for the biosynthesis of these oxylipins are lipoxygenases (LOX),
cyclooxygenases (COX), and cytochrome P450 enzymes (CYP). AA conversion by LOX results in the
production of hydroxyeicosatetraenoic acids (HETEs) or hydroxydocosahexaenoic acids (HDHAs)
with DHA as substrate. CYP are responsible for the production of epoxyeicosatrienoic acids (EETs)
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and hydroxyeicosapentaenoic acids (HEPEs). The main products of COX are prostaglandins. For a
review, see [8–11]. Several immuno-supportive properties are described for eicosanoids and other
lipid mediators. These includes vasomodulation [12], chemoattraction [13], and G protein-dependent
secretion of interleukin (IL)-6 and IL-8 [14]. Anti-inflammatory eicosanoids (e.g., 12-HETE, 15-HETE),
mainly block immune cell infiltration [15], inhibit secretion of interleukins [16] or activate the peroxisome
proliferator-activated receptor (PPAR) on immune cells [17]. Most research on eicosanoids is focused
on chronic diseases, including asthma or inflammatory bowel diseases [18,19]. However, the majority
of research on host eicosanoid profiles in infectious diseases is restricted to single infections with the
pathogens Escherichia coli [20], Borrelia burgdorferi [21], Pseudomonas aeruginosa [22], and IAV [5,23,24] or
focused solely on prostaglandin E2 [25–28] and its related receptors [28].
To our knowledge, lipid mediator profiling in bacterial, in particular S. pneumoniae and viral
co-infections, is unexplored (Table 1). Here, we used human bronchial epithelial cell line 16HBE [29–31]
for single and co-infections with IAV, S. aureus, and S. pneumoniae. Epithelial cells are the initial protective
barrier against viruses and bacteria and an important lung compartment to initiate immune system
regulation. It is well documented that IAV-mediated lung tissue damage increases the susceptibility
of the human host to secondary bacterial infections [32,33]. The analysis of the pathogen-mediated
changes in the intracellular lipid mediator profile could help to understand pathogen-specific host
immune responses in viral and bacterial single as well as co-infections.
Table 1. Overview of measured lipid mediators with precursor and involved major enzymes. Enzyme
abbreviations: lipoxygenase (LOX), cytochrome P450 (CYP), and cyclooxygenase (COX).
Precursor Key Enzymes Measured Lipid Mediators
arachidonic acid
5-LOX, 12-LOX, 15-LOX 5-HETE; 12-HETE; 15-HETE
CYPω-hydroxylase 20-HETE
CYP epoxygenases 5,6-EET; 8,9-EET; 11,12-EET; 14,15-EET
linoleic acid 15-LOX 9-HODE, 13-HODE
docosahexaenoic acid 12-LOX; 15-LOX 13-HDHA, 14-HDHA, 17-HDHA
eicosapentaenoic acid COX-2; CYP enzymes 18-HEPE
2. Results
2.1. Viability of 16HBE Post Infections
Most infections led to a minor, insignificant drop in cell viability (Figure S1). These included IAV
rH1N1 and S. pneumoniae TIGR4 single and respective co-infection. However, the strongest effects
were observed for S. aureus LUG2012 in single and co-infection with IAV rH1N1. The amount of vital
cells dropped down by approximately 50% (Figure S1).
2.2. Intracellular Lipid Mediator Profile in Response to Bacterial and Viral Single and Co-Infections
For all indicated infection conditions, we were able to detect 14 eicosanoids and oxylipins (Figure 1
and Table 1) out of 21 lipid mediators via our MRM method (Table S1). In general, a mixed profile of
AA, DHA, EPA, and LA derived lipid mediators was observed.
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Figure 1. Intracellular lipid mediator amounts in response to indicated bacterial and viral infections:
S. aureus LUG2012 (red), S. pneumoniae TIGR4 (blue), IAV rH1N1 (yellow), uninfected control (black)
and the co-infections IAV/S. aureus (orange), as well as IAV/S. pneumoniae (green). The bars denote mean
values ± standard deviations. For statistical analysis, the Mann–Whitney U-test was used for n = 15
(controls) and n = 4 (infections). The p-values were compared to a significance level α of 0.05 corrected
for multiple comparisons using Bonferroni correction for 9 clusters of oxylipins and 5 comparisons
resulting from infection conditions. Asterisks indicate significant changes.
Eicosanoids from AA conversion (HETEs) showed changes for all tested infections, whereas DHA-
and EPA-derived and analyzed lipids (HDHAs and 18-HEPE) were only affected by single infection
with S. pneumoniae TIGR4. In particular, the pro-inflammatory 5-HETE was elevated in all bacterial
infections, including co-infections (Figure 1). We detected a basal level of approximately 1.4 ng/sample
(control), which was significantly increased in all single bacterial and bacterial and viral co-infections.
The IAV single infection itself had no impact on 5-HETE production (Figure S2). In addition, increased
levels of 12-HETE were detected in both staphylococcal and pneumococcal mono infections.
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The majority of changes in the lipid mediator profiles were detected in S. pneumoniae infections.
Enhanced amounts of 15-HETE, 13-HODE, 18-HEPE, 13-HDHA, and 14-HDHA were exclusively
detected in pneumococcal infections (Figure 1 and Figure S2). Both anti-inflammatory lipids 13-HODE
and 18-HEPE showed high levels (fold change >3) under infection conditions compared to control.
In IAV single infections, only suppressive effects on the amounts of 8,9-EET and 9-HODE were observed.
The production of 9-HODE can be derived by enzymatic and autoxidation processes [34]. Moreover,
decreased levels of 20-HETE were detected in pneumococcal and IAV co-infections (Figure 1).
3. Discussion
Lipid mediator profiling of infected 16HBE cells revealed that 5-HETE might play a major
role at initial steps of bacterial infections of the respiratory tract. 5-HETE levels were significantly
increased in 16HBE cells infected with S. aureus LUG2012, S. pneumoniae TIGR4, and during the
corresponding co-infections with bacteria and IAV rH1N1, respectively. This observation may
indicate a prominent role of the pro-inflammatory metabolite 5-HETE in bacterial infections of the
bronchial compartment. 5-HETE is known to enable transcellular migration and aggregation of
neutrophils and to induce airway contraction [35,36]. This lipid mediator is generated from AA
within the 5-lipoxygenase (LO) pathway, encoded by the ALOX5 gene [37]. The interplay of 5-LO
with the nuclear membrane-associated 5-LO activating protein FLAP results in AA oxidation to
5-hydroxyperoxyeicosatrienoic acid (5-HpHETE). Subsequently, 5-HpHETE is than converted by
glutathione peroxidase to 5-HETE or to leukotrienes. Moreover, the different pro-inflammatory 5-LO
eicosanoids are associated with diseases like diabetes [38], Alzheimer [39], and atherosclerosis [40].
For example, leukotriene A4 can be converted to the pro-inflammatory leukotriene B4. Clementsen
et al. observed enhanced amounts of leukotriene B4 by antibody based detection in the supernatants
of human bronchoalveolar cells treated with inactivated S. aureus. However, this was not seen in
IAV-infected cells [41]. This indicates that, besides the pathogenic bacteria itself, toxins or bacterial
surface structures may also lead to alterations in eicosanoid production. Indeed, lipopolysaccharide
of Gram-negative bacteria is able to induce increased production of prostaglandins in endothelial
cells [42]. Furthermore, no changes in the 5-HETE production in response to IAV rH1N1 single infection
were observed. This is in line with other studies showing that IAV infections of mice [5,23], as well
as pigs [24], do not show changes for this lipid mediator, suggesting a lack of 5-LO activation by
IAV. In the pig IAV infection study [24], whole organs and BAL-fluid did not discriminate between
different cellular compartments, which can be obtained by single-cell experiments. However, a study
by Tam and colleagues showed increased levels of 5-HETE in nasopharyngeal washes of human high
responders during the 2009-2011 influenza seasons [5]. Whether such responses are linked to a certain
human organ, cellular compartment or host genetics remains to be elucidated. In contrast to other IAV
infection studies [5,23] using high pathogenic IAV strains, we used the rH1N1 (A/Bavaria/74/2009),
which is non-high pathogenic and more appropriate for co-infections. This could be a possible reason
for the missing 5-LO activation by IAV. However, the interplay between IAV and secondary bacterial
infection is complex. Thus it remains unclear how viral virulence and co-infection affect 5-HETE
production in the whole human lung, even if there are some suggestions that higher virulent IAV
strains increase rates of viral pneumonia and secondary bacterial infections together with associated
mortality [4,43,44].
Furthermore, we show that S. pneumoniae TIGR4 infections have the strongest impact on the
oxylipin profile. Induced 15-HETE and 13-HODE levels were exclusively seen in these infections.
Both 15-HETE and 13-HODE are PPARγ agonists. PPARγ is a ligand-activated transcription factor, and it
is known for its anti-inflammatory properties. These include downregulation of the cyclooxygenase-2
gene [45], inhibition of NF-κB [46], or reduced production of pro-inflammatory cytokines and
interleukins through its action on macrophages [47]. The group of Solleti et al. [48] showed that the
loss of epithelial PPARγ in the lung leads to increased inflammatory mediator production. This could
explain why enhanced PPARγ activation is necessary for the resolution of inflammation.
Metabolites 2020, 10, 113 5 of 10
Furthermore, we observed decreased amounts of 20-HETE in co-infections with S. pneumoniae.
A relationship between changes in levels of 20-HETE and immune suppression in the context of
immunosuppressant medication is described [49]. Nevertheless, the role of this lipid mediator in the
context of inflammation is rarely explored.
In line with this, elevated amounts of other anti-inflammatory lipid mediators (12-HETE or
18-HEPE) were also detected in pneumococcal infected 16HBE cells. The simultaneous increase of both
oxylipins with pro-inflammatory (5-HETE) and anti-inflammatory properties (15-HETE and 13-HDHA)
was also documented in IAV-mediated respiratory tract infections of mice [23]. However, our study
shows, for the first time, such a mixed profile in S. pneumoniae infections. For further studies, infection
experiments that are closer to in vivo conditions of tissues like air–liquid interface cell culture should
be taken into account for verification of our findings.
4. Materials and Methods
4.1. Chemicals
Lipid mediators and the deuterated standards 12-HETE-d8 and 13-HODE-d4 were purchased
from Cayman chemicals. 12-HETE-d8 and 13-HODE-d4 were dissolved in acetonitrile (both 100 ng/ml
as internal standard) on ice and aliquots were stored at −80 ◦C until usage. Acetonitrile (MS grade)
was purchased from Th. Geyer®, methanol from Roth®, and acetic acid (HPLC grade) from VWR®.
Solid-phase extraction cartridges Bond Elut Certify II (3 mL, 200 mg) were obtained from Agilent®.
BHT and other chemicals, including hexane, ethyl acetate, and sodium hydroxide were purchased
from Sigma-Aldrich.
4.2. Cell Culture
16HBE14o- (16HBE) cells were a gift from Dieter Gruenert (Mt Zion, Cancer Center, San Francisco,
CA, USA). The cells were cultured in MEM medium (Gibco) supplemented with 10% (v/v) fetal bovine
serum (FBS; Life Technologies), 2 mM L-glutamine (Invitrogen), 10 mM HEPES (GE Healthcare) and
1% (v/v) Minimal Essential Amino Acids (GE Healthcare) in fibronectin-coated flasks (Corning) at
37 ◦C and 5% CO2 atmosphere.
4.3. Bacterial and Virus Strains
Streptococcus pneumoniae serotype 4 strain TIGR4 was grown on Columbia blood agar plates (Oxoid)
and cultivated to mid-log phase (A600 0.35–0.4) in Todd–Hewitt broth (Roth) containing 0.5% (w/v) yeast
extract (Roth) at 37 ◦C and 5 % CO2. Staphylococcus aureus strain LUG2012 (USA300 lineage) [50] was
cultured overnight at 37 ◦C in casein hydrolysate and yeast extract (CCY) medium with agitation [51].
Influenza virus A/Bavaria/74/2009 (rH1N1) was propagated and cultivated, as described by Eisfeld
and colleagues [52].
4.4. Cell Culture Infections Experiments
16HBE cells were seeded in T175 culture flasks and grown to approximately 80% confluence.
For calculation of the multiplicity of infection (MOI), cell counts of the control flask were determined.
The flasks were either left untreated or were infected with rH1N1 at MOI 0.1 for 24 h. This amount
of virus and the time point were determined as an optimal infection with no significant cell death.
After 24 h, bacterial infections of uninfected and rH1N1 infected cells were performed. TIGR4
infections were conducted at MOI 50 for 2 h, followed by 4 h of antibiotic treatment (200 µg/mL
gentamycin (Sigma Aldrich, St. Louis, MS, USA), 100 U/mL penicillin G (HighClone™)). LUG2012
infections were conducted at MOI 10 for 2 h followed by 4 h of antibiotic treatment (550 µg/mL
gentamycin, 280 U/mL penicillin G, 280 µg/mL streptomycin, 5 U/mL lysostaphin (Sigma Aldrich)).
Uninfected or rH1N1 infected cells served as controls. Controls received the same antibiotic treatment.
After antibiotic treatment, cells were detached using a scraper and counted. The cell number was
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used for the normalization of oxylipin amounts (10 million cells per sample) for both absolute and
relative quantified lipid mediators. The cells were harvested by centrifugation at 4 ◦C and the cell
pellets were suspended in 500 µL ice-cold methanol supplemented with 0.1% BHT and 500 µL ice-cold
water (HPLC–MS grade) and stored at −80 ◦C.
4.5. Oxylipin Extraction
The frozen cell pellets were thawed on ice and immediately transferred in a 2-mL tube containing
FastPrep™ lysing matrix D and 100 µL internal standard was added. The cells were lysed for 45 s with
6 m/s using a FastPrep™. The supernatant was transferred into a new glass tube on ice. The lysing matrix
was washed with 250 µL ice-cold water and 250 µL ice-cold methanol containing 0.1% BHT, then a
second lysing cycle was performed and both supernatants were combined. Afterwards, an alkaline
hydrolysis step and solid-phase extraction was performed as previously described [24].
4.6. HPLC-MS/MS Measurement
After drying under nitrogen flow (TurboVap®, Biotage®), the extract was reconstituted in 70 µL
80% ACN and measured (10 µL injection volume) with an Agilent® HPLC system (1200 series),
coupled to an Agilent® 6460 Triple quadrupole mass spectrometer with electrospray ionization source
in negative mode. The mobile phase was water with 0.05% acetic acid (A) and ACN (B). The gradient,
column, and MS parameters are referred to in [24]. Using dynamic multiple reaction monitoring (MRM)
measurements, the identification was done by standard compounds (MRM transitions, retention times,
and optimized parameters can be found in Table S1).
4.7. Quantification and Statistics
Absolute quantification for HETEs and EETs was done using calibration curves (concentration
range between 0.1 and 50 ng/sample; curve type quadratic, weighting 1/x) with MS-certified standards
and 12-HETE-d8 as an internal standard. HEPE, HDHAs, and HODEs were normalized to the internal
standard response (HEPE and HDHAs to 12-HETE-d8; HODEs to 13-HODE-d4) and stated as “relative
amounts” in the plots. For absolute and relative quantified amounts of lipid mediators, the data were
normalized to 10 million cells per sample. Data analysis was performed with Agilent Mass Hunter
Qualitative and Quantitative Analysis software (version B.07.00 for both). Infection experiments
were done with four biological replicates and 15 biological replicates for control (non-infection)
experiments. Statistics were done using the Mann–Whitney U-test with Graph Pad Prism (version 7.05).
The p-values were adjusted for multiple comparisons (control vs. three different mono-infections and
two different co-infections) and the number of oxylipins using Bonferroni’s correction. The strength
of the relationship between the measured lipid mediators was tested by correlation analysis after
Spearman (ρ > 0.75) and resulted in the integration of all EETs and all HDHAs into two clusters under
the inclusion of their biosynthesis. The clustering reduced the number of oxylipins used to calculate the
factor of Bonferroni correction. The p-values obtained after correction were compared to a significance
level α of 0.05. Both p-values and results from the correlation analysis can be found in Supplementary
Materials (Tables S2 and S3).
5. Conclusions
In summary, the presented study demonstrates alterations in the oxylipin profile of 16HBE cells in
response to different viral and bacterial mono and co-infections. The pro-inflammatory arachidonic acid
metabolite 5-HETE was shown to have a prominent role for all analyzed conditions involving bacteria,
which warrants further experimental studies to identify up-stream and down-stream mechanisms
driving lipid mediator production.
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Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/3/113/s1,
raw data. Figure S1: Survival rate of 16HBE cells under indicated infection conditions; 16HBE cells were infected
as described in the Materials and Methods section; 6 h post bacterial infections, the vital cells were detached and
counted; cell counts were normalized to the uninfected controls and are displayed as percentage of the uninfected
control. Figure S2: Heatmap displaying fold changes (infection/control) of measured lipid mediators; decreased
levels are shown in green and increased amounts in red. Table S1: Optimized MRM parameters for analyzed
lipid mediators with qualifier1 and quantifier2 ion; grey lipid mediators were not detected. Table S2: Calculated
p-values from Mann–Whitney test. Table S3: Spearman´s range correlation.
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